COMMUNIQUÉS West-GlobeNewswire

Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
07/04/2026
CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements
07/04/2026
Nasdaq confirms Company has regained compliance with Listing Rules 5550(b)(1) and 5620(a) SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical‑stage pharmaceutical [...]
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
07/04/2026
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's [...]
Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
07/04/2026
CALGARY, Alberta, April 07, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company” ), a drug [...]
Everbright Health Announces AI-Enabled Platform to Unlock Access to Advanced Mental Health Interventions
07/04/2026
New Platform Streamlines Path from Eligibility to Care for Patients Who Are Resistant to Standard Treatments SAN FRANCISCO, April 07, 2026 (GLOBE NEWSWIRE) -- Everbright Health, an AI-enabled services platform that [...]
Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption
07/04/2026
New dedicated billing code facilitates payer reimbursement, supports clinician adoptions, and enables national utilization tracking HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“ [...]
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
07/04/2026
PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president [...]
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
07/04/2026
Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S. sales efforts for [...]
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
07/04/2026
Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design Additional data from MRI analyses will also be featured at [...]
Virbac : Declaration of the number of shares and voting rights 03/2026
07/04/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de votes 03/2026
07/04/2026
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
07/04/2026
COPENHAGEN, Denmark, April 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to [...]
Transactions in connection with share buy-back program
07/04/2026
Company announcement no. 9 - 26 07 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Oculis to Participate in Upcoming Investor Conferences
07/04/2026
ZUG, Switzerland, April 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]
SonoNeu exits stealth as key part of US Government-funded research program worth up to $41.3m to advance sonogenetics into clinic
07/04/2026
Sonogenetics, discovered by SonoNeu founder Sreekanth Chalasani, is a new modality using ultrasound to precisely control specific cells ‘tagged’ with special proteins SonoNeu is part of a collaborative project, also [...]
SPINEWAY : Compte-rendu de l’Assemblée Générale du 2 avril 2026
07/04/2026
Ecully, le 7 avril 2026 – 8h00 SPINEWAY Compte-rendu de l’Assemblée Générale du 2 avril 2026 L'Assemblée Générale Mixte (Ordinaire et Extraordinaire) des actionnaires de Spineway s'est tenue sur première convocation ce [...]
SPINEWAY : Minutes of the General Meeting of April 2, 2026
07/04/2026
Ecully, April 7, 2026 – 8:00 a.m. SPINEWAY Minutes of the General Meeting of April 2, 2026 The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Thursday 2 April [...]
Pharming Group to participate in April investor conferences
07/04/2026
Leiden, the Netherlands, April 7, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences in the month [...]
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
07/04/2026
Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma [...]

Pages